{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:52:17Z","timestamp":1793321537083,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2026,4]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n We assessed whether baseline urine albumin-creatinine ratio (UACR) and eGFR modify treatment effects on UACR reduction and safety in the CONFIDENCE trial.<\/jats:p>\n <\/jats:list-item>\n \n Higher baseline eGFR or UACR, age, female sex, and atherosclerotic cardiovascular disease were associated with greater albuminuria lowering at 6 months (180 days).<\/jats:p>\n <\/jats:list-item>\n \n Treatment effects on efficacy and safety were consistent, with no significant heterogeneity across baseline UACR or eGFR groups.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n In the CONFIDENCE trial, simultaneous initiation of finerenone (10 or 20 mg) and empagliflozin (10 mg) was superior to either monotherapy in reducing albuminuria at 180 days in participants with type 2 diabetes and CKD. In this analysis, we evaluated whether baseline urine albumin-creatinine ratio (UACR) and eGFR were associated with the magnitude of UACR reduction, and whether baseline UACR and eGFR modify the effect of combination treatment.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n In this\n post hoc<\/jats:italic>\n analysis of the CONFIDENCE trial (\n n<\/jats:italic>\n =796), linear mixed-effects models were used to evaluate the effects of baseline UACR and eGFR on the change in UACR from baseline using subgroups on the basis of clinically relevant thresholds of UACR (<300 versus \u2265300 mg\/g) and eGFR (<60 versus \u226560 ml\/min per 1.73 m\n 2<\/jats:sup>\n ). Logistic regression models were used to assess the odds of achieving UACR reductions at day 180.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n At day 180, higher baseline eGFR (per 10 ml\/min per 1.73 m\n 2<\/jats:sup>\n ) was independently associated with a \u22127% (95% confidence interval [CI], \u221211 to \u22124) greater reduction in UACR (\n P<\/jats:italic>\n < 0.001), and higher baseline UACR (per log change of UACR) was independently associated with a \u22129% (95% CI, \u221214 to \u22123) greater reduction in UACR (\n P<\/jats:italic>\n < 0.001). However, the treatment effect of finerenone, empagliflozin, or their combination on changes in UACR levels was not modified by baseline levels of eGFR or UACR. Besides the use of combination therapy, independent predictors of >30% reduction in UACR were age (odds ratio [OR], 1.23 per 10 years [95% CI, 1.05 to 1.45]), female sex (OR, 1.95 [95% CI, 1.32 to 2.86]), and atherosclerotic cardiovascular disease (OR, 1.63 [95% CI, 1.13 to 2.35]). The safety end points showed no significant heterogeneity across UACR or eGFR.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Overall, greater albuminuria lowering was seen with a higher baseline eGFR or UACR, older age, in female patients, and those with atherosclerotic cardiovascular disease, irrespective of the treatment. Albuminuria-lowering with combination therapy, finerenone, or empagliflozin treatment effects were independent of baseline eGFR or UACR.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number:<\/jats:title>\n ClinicalTrials.gov, NCT05254002; European Union Drug Regulating Authorities Clinical Trials Database 2021-003037-11.<\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.0000000928","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:00:09Z","timestamp":1762448409000},"page":"764-776","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both"],"prefix":"10.1681","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4258-1726","authenticated-orcid":false,"given":"Amy","family":"Mottl","sequence":"first","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-4889","authenticated-orcid":false,"given":"Charlie","family":"Scott","sequence":"additional","affiliation":[{"name":"Bayer Healthcare Inc., Whippany, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9967-5352","authenticated-orcid":false,"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"University of Groningen and University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3154-5332","authenticated-orcid":false,"given":"Johannes F.E.","family":"Mann","sequence":"additional","affiliation":[{"name":"KfH Kidney Centre Munich and Friedrich Alexander University, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-6521","authenticated-orcid":false,"given":"Janet B.","family":"McGill","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7401-2934","authenticated-orcid":false,"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[{"name":"The University of Tokyo Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-3275","authenticated-orcid":false,"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Velocity Clinical Research at Medical City, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen and University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Bayer Healthcare, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-7100","authenticated-orcid":false,"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the CONFIDENCE Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"issue":"6","key":"B3-20260525","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J."},{"issue":"2","key":"B4-20260525","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med."},{"issue":"24","key":"B5-20260525","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"issue":"15","key":"B6-20260525","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"6","key":"B7-20260525","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med."},{"issue":"22","key":"B8-20260525","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2012.16817","article-title":"Age and association of kidney measures with mortality and end-stage renal disease","volume":"308","author":"Hallan","year":"2012","journal-title":"JAMA."},{"issue":"9854","key":"B9-20260525","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet."},{"issue":"10365","key":"B10-20260525","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet."},{"issue":"23","key":"B11-20260525","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"issue":"4","key":"B12-20260525","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant."},{"issue":"8","key":"B13-20260525","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/ndt\/gfaf022","article-title":"COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint (CONFIDENCE) trial: baseline clinical characteristics","volume":"40","author":"Agarwal","year":"2025","journal-title":"Nephrol Dial Transplant."},{"issue":"9","key":"B14-20260525","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"issue":"1","key":"B15-20260525","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","article-title":"Modification of the CKD Epidemiology Collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates","volume":"56","author":"Horio","year":"2010","journal-title":"Am J Kidney Dis."},{"issue":"4S","key":"B16-20260525","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"issue":"8","key":"B17-20260525","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamacardio.2023.1505","article-title":"Modifiability of composite cardiovascular risk associated with chronic kidney disease in type 2 diabetes with finerenone","volume":"8","author":"Agarwal","year":"2023","journal-title":"JAMA Cardiol."},{"issue":"1","key":"B18-20260525","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"B20-20260525","doi-asserted-by":"crossref","first-page":"e2112828","DOI":"10.1001\/jamanetworkopen.2021.12828","article-title":"Progression and regression of chronic kidney disease by age among adults in a population-based cohort in Alberta, Canada","volume":"4","author":"Liu","year":"2021","journal-title":"JAMA Netw Open."},{"issue":"4","key":"B21-20260525","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/dom.16190","article-title":"Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: a combined analysis from the CANVAS program and CREDENCE trial","volume":"27","author":"Siriwardana","year":"2025","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"B22-20260525","doi-asserted-by":"crossref","first-page":"e076444","DOI":"10.1136\/bmjopen-2023-076444","article-title":"Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials","volume":"14","author":"Bansal","year":"2024","journal-title":"BMJ Open."},{"issue":"3","key":"B23-20260525","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ekir.2021.11.018","article-title":"Sex-specific differences in mortality and incident dialysis in the chronic kidney disease outcomes and practice patterns study","volume":"7","author":"Hecking","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B24-20260525","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-023-00784-z","article-title":"Differences in the epidemiology, management and outcomes of kidney disease in men and women","volume":"20","author":"Chesnaye","year":"2024","journal-title":"Nat Rev Nephrol."},{"issue":"2","key":"B25-20260525","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.semnephrol.2022.04.007","article-title":"Sex and gender related differences in diabetic kidney disease","volume":"42","author":"Sridhar","year":"2022","journal-title":"Semin Nephrol."},{"issue":"4","key":"B26-20260525","doi-asserted-by":"crossref","first-page":"e216139","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open."},{"issue":"10166","key":"B27-20260525","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet."},{"issue":"1","key":"B28-20260525","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ehjcvp\/pvac054","article-title":"Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease","volume":"9","author":"Filippatos","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"12","key":"B29-20260525","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis","volume":"176","author":"Agarwal","year":"2023","journal-title":"Ann Intern Med."},{"issue":"3","key":"B30-20260525","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1161\/01.HYP.0000178102.85718.66","article-title":"Correlates of systolic hypertension in patients with chronic kidney disease","volume":"46","author":"Agarwal","year":"2005","journal-title":"Hypertension."},{"issue":"6","key":"B31-20260525","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1161\/01.HYP.0000164577.81087.70","article-title":"Control of hypertension in adults with chronic kidney disease in the United States","volume":"45","author":"Peralta","year":"2005","journal-title":"Hypertension."},{"issue":"4","key":"B32-20260525","doi-asserted-by":"crossref","first-page":"108411","DOI":"10.1016\/j.jdiacomp.2023.108411","article-title":"Design and rationale of FINE-REAL: a prospective study of finerenone in clinical practice","volume":"37","author":"Desai","year":"2023","journal-title":"J Diabetes Complications."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:42:29Z","timestamp":1786131749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000928"}},"subtitle":["Post Hoc Analyses of CONFIDENCE Trial"],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000000928","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"2025-09-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}